7th Closed Scientific Expert Meeting of the Editorial Board
An update on inclisiran
Reports from the 7th Expert Meeting of PCSK9 Forum Kausik Ray
read more »
An update on cardiovascular disease, depression and adherence
Reports from the 7th Expert Meeting of PCSK9 Forum David Hare
read more »
A background to siRNA: Pushkal Garg, Alnylam
Reports from the 7th Expert Meeting of PCSK9 Forum Pushkal Garg
read more »
How do we identify very high risk patients for PCSK9 inhibition? Part Two
Reports from the 7th Expert Meeting of PCSK9 Forum The role of imaging: Ulf Landmesser, Charité Universitätsmedizin Berlin, Germany
read more »
How do we identify very high risk patients for PCSK9 inhibition? Part One
Reports from the 7th Expert Meeting of PCSK9 Forum Clinical profiling: Erik Stroes, Academic Medical Center, the Netherlands
read more »
Profiling patients with ACS: What are the prospects for PCSK9 inhibition?
Reports from the 7th Expert Meeting of PCSK9 Forum Gregory G. Schwartz, VA Medical Center and University of Colorado School of Medicine, Denver
read more »
PCSK9 and the beta-cell
PCSK9 is expressed in human pancreatic islets, where it down-regulates LDLR expression. But what are the effects of PCSK9-deficiency on glucose homeostasis and insulin secretion? Dr Betrand Cariou (l’Institut du Thorax Université de Nantes, France) overviews the evidence from studies to date.
read more »
Intracellular actions of PCSK9
Reports from the 7th Expert Meeting of PCSK9 Forum The hepatic extracellular function of PCSK9 in inhibiting the LDL receptor is now well established. With the development of novel agents that block PCSK9 synthesis upstream, investigation of intracellular actions of PCSK9 is a new focus…
read more »
